Ray Boyapati: has no known conflicts of interest.

Joana Torres: has received fees from Takeda for consultancy; and fees for travel, accommodation or meeting expenses from AbbVie and Ferring. All of these activities are outside the submitted work.

Carolina Palmela: has no known conflicts of interest.

Claire E Parker: has no known conflicts of interest.

Orli M Silverberg: has no known conflicts of interest.

Sonam D Upadhyaya: has no known conflicts of interest.

Reena Khanna: has received consulting fees from AbbVie, Janssen, Pfizer, Shire, and Takeda. All of these activities are outside the submitted work.

Vipul Jairath: has received scientific advisory board fees from Abbvie, Sandoz, Ferring and Janssen; speaker's fees from Takeda and Ferring; and travel support for conference attendance from Vifor pharmaceuticals. All of these activities are outside the submitted work.

Brian G Feagan: has received fee(s) from Abbott/AbbVie, Amgen, Astra Zeneca, Avaxia Biologics Inc., Bristol‐Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Ferring, JnJ/Janssen, Merck, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Takeda, Teva, Tillotts Pharma AG, UCB Pharma for Board membership; fee(s) from Abbott/AbbVie, Actogenix, Albireo Pharma, Amgen, Astra Zeneca, Avaxia Biologics Inc., Axcan, Baxter Healthcare Corp., Boehringer‐Ingelheim, Bristol‐Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, GiCare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Merck, Millennium, Nektar, Novonordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, Tillotts, UCB Pharma, Vertex Pharma, Warner‐Chilcott, Wyeth, Zealand, and Zyngenia for consultancy; and lecture fee(s) from: Abbott/AbbVie, JnJ/Janssen, Takeda, Warner‐Chilcott, and UCB Pharma. All of these activities are outside the submitted work.

Jean‐Frédéric Colombel has received consulting fees from Abbvie, Amgen, Boehringer‐Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring, Genentech, Janssen Pharmaceuticals, Medimmune, Merck &Co, Pfizer, Protagonist, Second Genome, Seres, Shire, Takdea, Theradiag and Theravance Biopharma; grants/grants pending from Abbvie, Takeda, Janssen Pharmaceuticals; payment for lectures and speakers bureaus from AbbVie, Ferring, Pfizer, Takeda and Shire; and stock/stock options from Intestinal Biotech Development and Genfit. All of these activities are outside the submitted work.